PEAK PROCESSING LIMITED — Regulatory Filings 2019

Nov 12, 2019

==> picture [595 x 147] intentionally omitted <==

ASX Announcement | 13 November 2019 Althea Group Holdings (ASX:AGH)

Althea to supply product for clinical trial exploring use of cannabis medicines in treatment of advanced cancer symptoms

INVESTMENT HIGHLIGHTS:

• Althea enters agreement with the NHMRC-funded Australian Centre for Cannabinoid Clinical and Research Excellence (through the University of Newcastle) to be one of the product suppliers for a clinical trial exploring the use of cannabis medicines in the treatment of advanced cancer symptoms

• • Cannabis medicines will be supplied by Althea on a commercial basis

13 November 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce that it has entered an agreement with the Australian Centre for Cannabinoid Clinical and Research Excellence (through the University of Newcastle) to supply product for the Cannabinoid for Symptom Control in Advanced Cancer, An Open Label Prospective Clinical Trial in New South Wales (CARE NSW).

Under the agreement, as one of several suppliers, Althea will supply two cannabis medicines for the Trial. The target number of patients for the trial is up to 600 and Althea’s products will be supplied to Australian Centre for Cannabinoid Clinical and Research Excellence (through the University of Newcastle) on commercial terms. Under this arrangement, the CARE NSW Trial does not guarantee Althea a minimum or maximum quantity of investigational product to be purchased.

Althea CEO Josh Fegan said: “Althea is proud to be one of the companies supplying cannabis medicines to the Australian Centre for Cannabinoid Clinical and Research Excellence’s clinical trial. We are big believers in the potential benefits of medicinal cannabis and pleased to support an initiative such as this, which will further our scientific understanding of its use in areas of unmet needs. We look forward to the results of the CARE NSW Trial.”

-ENDS-

For further information, please contact:

Althea Media Enquiries Josh Fegan Julia Maguire CEO & Managing Director The Capital Network M: 1300 70 20 20 M: +61 419 815 386 E: contact@althea.life E: julia@thecapitalnetwork.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

==> picture [595 x 92] intentionally omitted <==